Competitive Rivalry

COVID vaccine demand normalized sharply, so Moderna now competes in a smaller, more price-sensitive mRNA vaccine market than during the pandemic peak.

Pfizer/BioNTech’s Comirnaty and other large-cap vaccine franchises create heavier commercial pressure on Moderna’s respiratory pricing than on niche biotech peers.

Pipeline overlap in RSV, flu, and combination vaccines raises rivalry because differentiated clinical data, not brand alone, increasingly determines share and reimbursement.

Threat Of New Entrants

High regulatory, manufacturing, and clinical-development barriers limit new entrants, preserving industry economics for established mRNA platforms versus smaller biotech start-ups.

Moderna’s scale in mRNA process development and global regulatory experience creates a structural advantage over entrants that lack validated commercialization infrastructure.

However, large pharma can still enter through partnerships or acquisitions, so barriers protect margins less completely than in highly concentrated biologics markets.

Bargaining Power Of Suppliers

Specialized lipid nanoparticles, nucleotides, and fill-finish capacity can tighten supply economics, but these inputs are not as scarce as in ultra-complex cell therapy.

Moderna’s large procurement scale and multi-sourcing reduce supplier leverage relative to smaller mRNA developers that depend on single vendors.

Contract manufacturing remains a meaningful cost pass-through risk, yet supplier power is moderated because major pharma peers face similar external capacity constraints.

Bargaining Power Of Buyers

Governments, payers, and large health systems negotiate aggressively on vaccine pricing, leaving Moderna with limited ability to sustain pandemic-era margins.

Buyer concentration is high in vaccines, so reimbursement and tender dynamics pressure Moderna more than diversified peers with broader therapeutic portfolios.

As COVID volumes fade, buyers can compare multiple respiratory options, which weakens Moderna’s pricing power unless products show clear incremental efficacy.

Threat Of Substitutes

Traditional protein-based vaccines and emerging non-mRNA platforms substitute for several respiratory indications, limiting Moderna’s ability to command premium pricing.

For some targets, established prophylactic standards and combination regimens reduce the urgency of switching to mRNA, especially when efficacy differences are modest.

Moderna’s platform remains differentiated in speed and adaptability, but substitutes constrain long-run margin expansion versus peers with more protected therapeutic niches.

Overall Score

Moderna’s industry structure is mixed: high entry barriers support long-run platform economics, but intense buyer pressure, normalized vaccine demand, and credible substitutes materially cap pricing power versus global peers.